Pancreatic ductal adenocarcinoma (PDAC) is characterized by dense stromal reaction, which can promote tumor progression and contribute to chemo-resistance. The dense stroma can serve as a barrier to drug perfusion into the tumor by creating high intra-tumoral interstitial pressure. The dense stromal matrix in PDAC is caused by overproduction of extracellular matrix (ECM), mainly composed of collagens and hyaluronan. Hyaluronan is synthesized by HA synthase enzymes (HASs) and degraded by hyaluronidases (HYALs). Our previous work and other studies have shown that BRD4 protein, which is the most important member of bromodomain and extraterminal domain (BET) family proteins, is overexpressed in PDAC. BET proteins are ?readers? of acetylated chromatin marks. Treatment with BET inhibitors also decreases tumor growth in PDAC mouse models. In this grant application, we propose our novel hypotheses that (1) BET protein inhibition decreases HA accumulation in PDAC tumors by decreasing the HA production. We further hypothesize that (2) BET inhibition will block receptor for HA-mediated motility (RHAMM)- driven oncogenic HA signaling. These hypotheses are based on strong preliminary data. We propose two specific aims.
Aim 1 : Investigate the role of BET proteins regulating HA levels in PDAC tumors and molecular mechanisms through which.
Aim 2 : Determine the ability of BET inhibitors to block HA signaling. This proposal includes innovative concept of HA regulation in PDAC, and has high biological and clinical relevance and significance, with potential for developing new therapeutic strategies for PDAC.

Public Health Relevance

The proposed research is relevant to public health because the current proposal seeks to target the enzymes and receptor involved in hyaluronan synthesis and hyaluronan-mediated signaling in pancreatic cancer is ultimately expected to help identify novel therapeutic strategies to overcome the chemo-resistance in this highly lethal malignancy. Thus, the proposed research is relevant to the mission of the NIH that pertains to improving the health of the Nation by supporting research in the cure/treatment of human disease.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21CA220625-02
Application #
9571246
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Schwartz, Elena Ivan
Project Start
2017-09-25
Project End
2019-08-31
Budget Start
2018-09-01
Budget End
2019-08-31
Support Year
2
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Northwestern University at Chicago
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
005436803
City
Chicago
State
IL
Country
United States
Zip Code
60611